The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Q4 2024 dividend of 16p declared; 61p FY 2024; 64p expected for 2025. GSK (GSK) now intends to commence a GBP 2B share buyback programme, to be ...

GSK (GSK) provides its full-year guidance at constant exchange rates; Turnover is expected to increase between 3% to 5%. Core operating profit ...

Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year.

(PRESS RELEASE) LONDON, 1-Feb-2025 — /EuropaWire/ — In a significant development for HIV treatment, ViiV Healthcare, majority owned by GSK plc, has received approval from the European Commission for ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...

GSK plc announced that new drug applications have been accepted for review by the China National Medical Products Administration (NMPA) and submitted to the Japanese Ministry of Health, Labour and ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation ...